A recent systematic review of 17 clinical trials in which Ad-p53 was used in combination with TACE for the treatment of HCC found that the addition of recombinant p53 resulted in improved overall survival and quality of life compared to standard monoagent TACE therapy [362]. This evidence concerns the gene TP53 and hepatocellular carcinoma.